setrusumab

Monoclonal antibody

Negativelead readout

Evidence outlook · lead readout

Cosmic (NCT05768854) · Osteogenesis Imperfecta

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found. A further registrational readout is expected around 2027-01.

Cosmic (NCT05768854): The trial was randomized and used an active comparator (bisphosphonate) rather than placebo, with a genuine hard clinical endpoint (fracture rate), but it was open-label with no blinding and enrolled only 69 children. The primary comparison showed a numerical advantage for setrusumab that did not reach statistical significance, so despite reasonable design elements this is evidence of an unclear/negative effect rather than a proven benefit.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Osteogenesis Imperfecta
NCT06636071 · Ultragenyx Pharmaceutical Inc
2024-10-25 – 2028-01 · Osteogenesis Imperfecta
What this study did
Phase 2/3 (1)
Osteogenesis Imperfecta
Phase 2 (2)
Osteogenesis Imperfecta
NCT05312697 · Ultragenyx Pharmaceutical Inc
2022-04-28 – 2022-07-07 · Osteogenesis Imperfecta
What this study did
NCT03118570 · Ultragenyx Pharmaceutical Inc
2017-09-11 – 2020-11-12 · Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow setrusumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 3Osteogenesis ImperfectaActive not recruiting
Est. primary completion 2027-01 · NCT06636071 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 December 2025Topline resultPhase 3 Orbit (NCT05125809) and Cosmic of setrusumab did not meet their primary fracture-rate endpoints